7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.1016/j.iotech.2022.100246
Copy DOIJournal: Immuno-Oncology and Technology | Publication Date: Dec 1, 2022 |
License type: cc-by-nc-nd |
134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.